相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban
Rita Carolina Figueiredo Duarte et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Calibrated automated thrombogram II: removing barriers for thrombin generation measurements
P. L. A. Giesen et al.
THROMBOSIS JOURNAL (2021)
Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing
Jonathan Evrard et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants
Jack Ansell et al.
BLOOD (2021)
Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months
Geoffrey Foulon-Pinto et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation
Christian Pfrepper et al.
TRANSPLANT INTERNATIONAL (2021)
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
Mojca Bozic Mijovski et al.
SCIENTIFIC REPORTS (2021)
Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals
Zahir Kanjee et al.
JAMA NETWORK OPEN (2021)
Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants
Michael Metze et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine
Francois Depasse et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study
Nina Haagenrud Schultz et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2021)
Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
Tuukka A. Helin et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing
Emmanouela Kampouraki et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran
Shusuke Takeshita et al.
ANESTHESIA AND ANALGESIA (2020)
Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays
Riyaad Aungraheeta et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation
Iqbal H. Jaffer et al.
ANNALS OF THORACIC SURGERY (2020)
Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation
Anica Petkovic et al.
BLOOD COAGULATION & FIBRINOLYSIS (2020)
Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation
Sylvie Perreault et al.
PHARMACOTHERAPY (2020)
Rivaroxaban in patients with mechanical heart valves: A pilot study
Eva Roost et al.
THROMBOSIS RESEARCH (2020)
Anticoagulant activity of edoxaban in patients with cirrhosis
Sarah Bos et al.
BLOOD (2020)
In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation
Maureen J. M. Werner et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Evaluation of the analytical performances of FibWave, a new sensitive tool assessing the fibrin clot formation, to measure the effects of anticoagulants
J. Evrard et al.
THROMBOSIS RESEARCH (2020)
Efficacy of pro- and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
Sarah Bos et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
Lorine Giffard-Quillon et al.
THROMBOSIS JOURNAL (2020)
Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes
Joseph R. Shaw et al.
THROMBOSIS RESEARCH (2020)
Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
Genmin Lu et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate
Roisin Bavalia et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
Michael Metze et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system
Christian Pfrepper et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers
Genmin Lu et al.
BLOOD ADVANCES (2020)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application
Jonathan Douxfils et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis
Eduardo Arellano-Rodrigo et al.
TRANSFUSION (2019)
Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability
Virginie Siguret et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors
Oliver Grottke et al.
ANESTHESIOLOGY (2019)
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome A Randomized Noninferiority Trial
Josep Ordi-Ros et al.
ANNALS OF INTERNAL MEDICINE (2019)
Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation
Saartje Bloemen et al.
THROMBOSIS RESEARCH (2019)
What we have learned about direct oral anticoagulant reversal
Deborah M. Siegal
Hematology-American Society of Hematology Education Program (2019)
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
Fakiha Siddiqui et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
J. H. Levy et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
J. Douxfils et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Vittorio Pengo et al.
BLOOD (2018)
In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis
Ton Lisman et al.
LIVER INTERNATIONAL (2018)
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide
Romain Siriez et al.
THROMBOSIS AND HAEMOSTASIS (2018)
The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma
Chi Zhang et al.
THROMBOSIS RESEARCH (2018)
Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay
Wil F. Kopatz et al.
THROMBOSIS RESEARCH (2018)
Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
Elias Kyriakou et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation
Saartje Bloemen et al.
THROMBOSIS RESEARCH (2018)
Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey
Tuukka A. Helin et al.
TRANSFUSION (2018)
Andexanet alfa for the treatment of hemorrhage
Andrea Cervi et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
\ Thrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observed
Joseph Rigano et al.
BLOOD COAGULATION & FIBRINOLYSIS (2018)
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction
Oliver Borst et al.
BLOOD ADVANCES (2018)
Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature
Joseph R. Shaw et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
Bettina Schenk et al.
THROMBOSIS JOURNAL (2018)
The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
Maureane Hoffman et al.
INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE (2018)
A review of commercially available thrombin generation assays
Jeremy Kintigh et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots
Stella Salta et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH
Y. Dargaud et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study
Y. Song et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement
Tuukka A. Helin et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers
Michael Schmohl et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays
Sandra Le Quellec et al.
THROMBOSIS RESEARCH (2017)
Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study
Sam Schulman et al.
THROMBOSIS RESEARCH (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Bethany T. Samuelson et al.
CHEST (2017)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
Ramin Artang et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro
Nina H. Schultz et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Nina Haagenrud Schultz et al.
THROMBOSIS JOURNAL (2017)
In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate
Stefano Barco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban
Huaibin Wan et al.
BLOOD COAGULATION & FIBRINOLYSIS (2016)
Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay
B. Schenk et al.
BRITISH JOURNAL OF ANAESTHESIA (2016)
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers
S. Nagalla et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation A Noninterventional Study
Argirios E. Tsantes et al.
MEDICINE (2016)
Edoxaban: Impact on routine and specific coagulation assays A practical laboratory guide
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2016)
A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation
Chikako Kamisato et al.
THROMBOSIS RESEARCH (2016)
Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation
Herm Jan M. Brinkman et al.
THROMBOSIS RESEARCH (2016)
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation
Fabrizio Semeraro et al.
THROMBOSIS RESEARCH (2016)
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Hannah Cohen et al.
Lancet Haematology (2016)
The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
Irina V. Gribkova et al.
SCIENTIFIC REPORTS (2016)
Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
Maureane Hoffman et al.
ANESTHESIOLOGY (2015)
Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
Genevieve Freyburger et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study
Elgar Oswald et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates - In Vitro Studies With Steady and Circulating Human Blood -
Gines Escolar et al.
CIRCULATION JOURNAL (2015)
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies
Elisabeth Perzborn et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Impact of dabigatran on platelet function and fibrinolysis
Argirios E. Tsantes et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers
Y. W. Cheung et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Multimodal assessment of non-specific hemostatic agents for apixaban reversal
A. -C. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah M. Siegal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban
Georges Jourdi et al.
THROMBOSIS AND HAEMOSTASIS (2015)
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
Stephan Glund et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin
Taketoshi Furugohri et al.
THROMBOSIS RESEARCH (2015)
From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples
Tuukka A. Helin et al.
THROMBOSIS RESEARCH (2015)
How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters
Armando Tripodi et al.
THROMBOSIS RESEARCH (2015)
Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism
D. R. J. Arachchillage et al.
THROMBOSIS RESEARCH (2015)
The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban
Karen S. Brown et al.
THROMBOSIS RESEARCH (2015)
Comparison of Methods to Determine Rivaroxaban anti-factor Xa activity
Suman Rathbun et al.
THROMBOSIS RESEARCH (2015)
Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists
Yuko Honda et al.
THROMBOSIS RESEARCH (2015)
Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers
Eduardo Arellano-Rodrigo et al.
TRANSFUSION MEDICINE REVIEWS (2015)
Laboratory Assessment of the Anticoagulant Activity of Dabigatran
Elias Kyriakou et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2015)
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
Hamim Zahir et al.
CIRCULATION (2015)
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
M. Levi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
E. Perzborn et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with Antiplatelet Agents under Flow and Static Conditions: An In Vitro Flow Chamber Model
Kazuya Hosokawa et al.
PLOS ONE (2014)
Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis
Wilma Potze et al.
PLOS ONE (2014)
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban
Richard Herrmann et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro
Elisabeth Perzborn et al.
THROMBOSIS RESEARCH (2014)
Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro
Yiming Xu et al.
BLOOD COAGULATION & FIBRINOLYSIS (2013)
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding A Randomized, Plasma-Controlled, Phase IIIb Study
Ravi Sarode et al.
CIRCULATION (2013)
Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation
Saartje Bloemen et al.
HAEMATOLOGICA (2013)
The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran
T. -L. Khoo et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Brian Dale et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
Meyer Michel Samama et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
John W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model
Oliver Grottke et al.
PLOS ONE (2013)
Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood
Gines Escolar et al.
PLOS ONE (2013)
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation
Pascal J. Molenaar et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2012)
Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method
R. Loeffen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke
Victor Serebruany et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
Raphael Marlu et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2012)
The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters
Laura Green et al.
THROMBOSIS RESEARCH (2012)
Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature
Jonathan Douxfils et al.
THROMBOSIS RESEARCH (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement
Genevieve Freyburger et al.
THROMBOSIS RESEARCH (2011)
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery
Yesim Dargaud et al.
BLOOD (2010)
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation
Laura Green et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Thrombin generation testing in haemophilia comprehensive care centres
Y. Dargaud et al.
HAEMOPHILIA (2010)
The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha(2)-macroglobulin-thrombin
R. J. Wagenvoord et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)
Alexander G. G. Turpie et al.
THROMBOSIS AND HAEMOSTASIS (2009)
Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thromblogram parameters
Joost J. Van Veen et al.
BLOOD COAGULATION & FIBRINOLYSIS (2008)
Thrombin generation in patients after acute deep-vein thrombosis
Arina J. ten Cate-Hoek et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation
Kenichi A. Tanaka et al.
THROMBOSIS RESEARCH (2008)
Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants
M. M. Samama et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study
Yesim Dargaud et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence
A. van Hylckama Vlieg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
G. T. Gerotziafas et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation
Gregor Hron et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor
Y Dargaud et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay
Grigoris T. Gerotziafas et al.
THROMBOSIS JOURNAL (2005)
The measurement and application of thrombin generation
T Baglin
BRITISH JOURNAL OF HAEMATOLOGY (2005)
分享论文
